Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK), ...
Daktari Diagnostics today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop Daktari’s ...
Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma Syndax Pharmaceuticals, ...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an ...
International Institute for Integrative Sleep Medicine, University of Tsukuba (“WPI-IIIS”) today announced a research collaboration agreement with Merck & Co., ...
Proteros to receive upfront and research funding plus milestone payments of up to $126 million plus royalties Proteros biostructures GmbH ...
Merck & Co., Inc. to make US$9 million investment in Bionomics Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on ...
Pivotal study to evaluate Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with advanced or metastatic melanoma ...
Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer MacroGenics, ...
Following the successful closure of the merger with drug maker Ranbaxy, Dilip Shanghvi-led Sun Pharma said on Wednesday that it ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
